Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study
Demjaha, Arsime; Galderisi, Silvana; Glenthøj, Birthe; Arango, Celso; Mucci, Armida; Lawrence, Andrew; O'Daly, Owen; Kempton, Matthew; Ciufolini, Simone; Baandrup, Lone; Ebdrup, Bjørn H; Rodriguez-Jimenez, Roberto; Diaz-Marsa, Maria; Díaz-Caneja, Covadonga Martinez; Winter van Rossum, Inge; Kahn, Rene; Dazzan, Paola; McGuire, Philip
(2023) Psychological medicine, volume 53, issue 8, pp. 3471 - 3479
(Article)
Abstract
Background Negative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively small patient samples, and the confounding effects of
... read more
chronic illness and exposure to antipsychotic medication. We sought to address these issues by investigating concurrently grey matter volumes (GMV) and cortical thickness (CTh) in a large sample of antipsychotic-naïve or minimally treated patients with First-Episode Schizophrenia (FES). Methods T1-weighted structural MRI brain scans were acquired from 180 antipsychotic-naïve or minimally treated patients recruited as part of the OPTiMiSE study. The sample was stratified into subgroups with (N = 88) or without (N = 92) Prominent Negative Symptoms (PMN), based on PANSS ratings at presentation. Regional GMV and CTh in the two groups were compared using Voxel-Based Morphometry (VBM) and FreeSurfer (FS). Between-group differences were corrected for multiple comparisons via Family-Wise Error (FWE) and Monte Carlo z-field simulation respectively at p < 0.05 (2-tailed). Results The presence of PMN symptoms was associated with larger left inferior orbitofrontal volume (p = 0.03) and greater CTh in the left lateral orbitofrontal gyrus (p = 0.007), but reduced CTh in the left superior temporal gyrus (p = 0.009). Conclusions The findings highlight the role of orbitofrontal and temporal cortices in the pathogenesis of negative symptoms of Schizophrenia. As they were evident in generally untreated FEP patients, the results are unlikely to be related to effects of previous treatment or illness chronicity.
show less
Download/Full Text
Keywords: Cortical thickness, first-episode psychosis, FreeSurfer, negative symptoms, voxel-based morphometry, Psychiatry and Mental health, Applied Psychology, Journal Article
ISSN: 0033-2917
Publisher: Cambridge University Press
Note: Funding Information: SG declares grants from the European Union; personal fees from Janssen, Janssen-Cilag Polska, Gedeon Richter, Recordati, Pierre Fabre, Angelini-Acraf, and Forum; and grants and personal fees from Otsuka. BG is the leader of a Lundbeck Foundation Center of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator initiated the study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. CA declares grants, personal fees, and other fees from Janssen-Cilag, Lundbeck, Otsuka, Acadia, Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, Cibersam, Fundación Alicia Koplowitz, Forum, Instituto de Salud Carlos III, Gedeon Richter, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Pfizer, Roche, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovio, and Takeda. AM received honoraria, advisory board or consulting fees from the following companies: Amgen Dompé, Angelini, Astra Zeneca, Bristol-Myers Squibb, Gedeon Richter Bulgaria, Innova- Pharma, Janssen Pharmaceutica, Lundbeck, Otsuka, Pfizer and Pierre Fabre. BHE has received lecture fees and/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company H. Lundbeck A/S. RRJ has been a consultant for, spoken in activities of, or received grants from Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Angelini. MDZ holds a grant from Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities, and has received honoraria from Abbvie and Sanofi. RSK declares personal fees for consultancy from Alkermes, Minerva Neuroscience, Gedeon Richter, and Otsuka; and personal (speaker) fees from Otsuka/Lundbeck. PD has received honoraria from Otsuka, Lundbeck, and Janssen. PM has received consultancy payment for Sunovion and Takeda. The remaining authors declare no competing interests. Funding Information: This study was funded by the European Commission Seventh Framework Program (HEALTH-F2-2010-242114). Publisher Copyright: Copyright © The Author(s), 2022. Published by Cambridge University Press.
(Peer reviewed)